Calcium-level responsive controlled drug delivery from implant dosage forms to treat osteoporosis in an animal model.
The effects of plasma calcium levels on estradiol release from a self-setting apatite bone cement containing 0.5% estradiol and on the bone mineral density (BMD) of ovariectomized rats were investigated. Apatite cement consisting of an equimolar mixture of tetracalcium phosphate, dicalcium phosphate dihydrate and 0.5% beta-estradiol was prepared. The in vitro release profiles from the cements in simulated body fluid containing 0, 5 and 10 mg/100 ml calcium indicated that estradiol release rate decreased with increasing calcium concentration in the dissolution medium. After subcutaneous implantation of the cement, in vivo estradiol release in diseased rats (ovariectomized rats on a low calcium diet) was significantly higher than that in normal rats. The diseased rats maintained a low calcium level during drug release. The bone mass of the recovery model rat was greater after the experiment than before. The results suggested that the severity of osteoporosis in this animals can be reduced by the implantation of this estradiol-loaded apatite cement.
Otsuka
M
M
Department of Pharmaceutical Technology, Kobe Pharmaceutical University, Motoyama-Kitamachi 4-19-1, Higashi-Nada, 658-8558, Kobe, Japan. m-otsuka@kobepharma.ac.jp
Matsuda
Y
Y
Baig
A A
AA
Chhettry
A
A
Higuchi
W I
WI
D000818:Animals; D001031:Apatites / Q000008:administration & dosage; D015519:Bone Density; D002118:Calcium / Q000097:blood*; D016503:Drug Delivery Systems; D004958:Estradiol / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D051381:Rats
D001031:Apatites; D004958:Estradiol; D002118:Calcium